David Irwin
Penn Neuroscience Center - Neurology
Office
(215) 316-5151
Fax (215) 349-5579 3400 Civic Center Boulevard Perelman Center for Advanced Medicine Philadelphia, PA 19104
Primary Specialty
Neurologist
Practice
Penn Neuroscience Center - Neurology
Gender
Male
Education
Drexel University College of Medicine
Training
Hahnemann University Hospital
About
My research program focuses on the interface of clinical symptoms and underlying neuropathology in neurodegenerative disease. The purpose of this approach is to better identify clinically, pathologically and genetically homogeneous patient populations for inclusion into clinical trials to efficiently study emerging disease modifying treatments that target the pathogenic proteins specific for each neuropathological subtype of disease (e.g. FTLD-associated with tau or TDP-43 protein inclusions). Currently, the diagnostic standard is neuropathological examination at autopsy, which is a major obstacle for clinical trials in neurodegenerative disease. To address this problem our approach is to "work backwards" to study human brain tissue and measure neuropathology objectively using novel open-source digital image analysis tools; We use a "tissue-guided biomarker discovery” method to translate our findings with the ultimate goal to develop new laboratory and imaging tests to detect pathology in living patients.
David Irwin
My clinical focus is on cognitive neurology and neurodegenerative disease including frontotemporal dementia, primary progressive aphasia, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, amyotrophic lateral sclerosis, progressive supranuclear palsy, corticobasal syndrome and multiple system atrophy. I have a particular interest in young-onset dementia and the behavioral variant of frontotemporal dementia.My research program focuses on the interface of clinical symptoms and underlying neuropathology in neurodegenerative disease. The purpose of this approach is to better identify clinically, pathologically and genetically homogeneous patient populations for inclusion into clinical trials to efficiently study emerging disease modifying treatments that target the pathogenic proteins specific for each neuropathological subtype of disease (e.g. FTLD-associated with tau or TDP-43 protein inclusions). Currently, the diagnostic standard is neuropathological examination at autopsy, which is a major obstacle for clinical trials in neurodegenerative disease. To address this problem our approach is to "work backwards" to study human brain tissue and measure neuropathology objectively using novel open-source digital image analysis tools; We use a "tissue-guided biomarker discovery” method to translate our findings with the ultimate goal to develop new laboratory and imaging tests to detect pathology in living patients.
Services
alzheimer's testing, lumbar puncture, neurocognitive testing, neuropsychological assessment
©2024 Wellness®.com is a registered trademark of Wellness.com, Inc. 